Management of indolent B-cell Lymphomas: A review of approved and emerging targeted therapies

Elizabeth Smyth; Chan Y Cheah; John F Seymour

doi:10.1016/j.ctrv.2023.102510

Management of indolent B-cell Lymphomas: A review of approved and emerging targeted therapies

Cancer Treat Rev. 2023 Feb:113:102510. doi: 10.1016/j.ctrv.2023.102510. Epub 2023 Jan 5.

Authors

Elizabeth Smyth¹, Chan Y Cheah², John F Seymour³

Affiliations

¹ Department of Hematology, Sir Charles Gairdner Hospital, Perth, Western Australia, Australia.
² Department of Hematology, Sir Charles Gairdner Hospital, Perth, Western Australia, Australia; Medical School, University of Western Australia, Perth, Western Australia, Australia. Electronic address: Chan.cheah@health.wa.gov.au.
³ Peter MacCallum Cancer Centre & The Royal Melbourne Hospital, Melbourne, Victoria, Australia; University of Melbourne, Victoria, Australia. Electronic address: John.seymour@petermac.org.

PMID: 36634434
DOI: 10.1016/j.ctrv.2023.102510

Abstract

The indolent B-cell non-Hodgkin lymphomas (B-NHL) comprise a heterogenous group of lymphoproliferative disorders characterized by slow growth kinetics and a relapsing/remitting course. Management has, until recently, been uniform across all indolent B-NHL subtypes. Improving insight into pathophysiological and molecular features of each disease has led to development of several targeted therapies. Consequently, each subtype must now be considered an individual entity. In this review, we consider the three commonest indolent B-NHLs: follicular lymphoma, marginal zone lymphoma and Waldenstrom's macroglobulinemia and review in detail the data on approved and emerging targeted therapeutic agents for each B-NHL subtype.

Keywords: Follicular lymphoma; Marginal zone lymphoma; Targeted therapies; Waldenstrom’s macroglobulinemia.

Publication types

Review

MeSH terms

Antineoplastic Agents* / therapeutic use
Humans
Lymphoma, B-Cell* / drug therapy
Lymphoma, B-Cell* / pathology
Lymphoma, Non-Hodgkin*

Substances

Antineoplastic Agents